<DOC>
	<DOCNO>NCT00049569</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Combining one chemotherapy drug imatinib mesylate may kill cancer cell . Randomized phase II trial study effectiveness combination chemotherapy imatinib mesylate treat child relapse acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Imatinib Mesylate Treating Children With Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility safety use intensified sequential induction regimen treat child acute lymphoblastic leukemia ( ALL ) , experience isolate , combine bone marrow relapse . II . To determine potential regimen serve , backbone , future test novel therapeutic agent . SECONDARY OBJECTIVES : I . To estimate remission re-induction rate four-month event-free survival ( EFS ) child , stratify duration first remission . II . To determine feasibility measure minimal residual disease ( MRD ) quantitatively patient time point throughout re-induction , correlate post-remission event disease burden induction . III . To use deoxyribonucleic acid ( DNA ) array characterize pattern gene expression predict treatment failure , compare gene expression profile time relapse time initial diagnosis gain understanding pathway may involve disease recurrence . IV . To determine feasibility combine intensive re-induction therapy imatinib mesylate ( STI571 ) child relapse Philadelphia chromosome positive ( Ph+ ) ALL . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Treatment Block 1 : Patients receive cytarabine intrathecally ( IT ) day 1 methotrexate IT day 15 29 . Patients also receive vincristine intravenously ( IV ) day 1 , 8 , 15 , 22 ; prednisone orally ( PO ) twice thrice daily ( BID TID ) day 1-29 ; pegaspargase intramuscularly ( IM ) day 2 , 8 , 15 , 22 ; doxorubicin IV 15 minute day 1 . Ph-positive patient also receive imatinib mesylate PO day 1-14 . Treatment Block 2 : Patients receive methotrexate IT day 1 22 , cyclophosphamide IV 30 minute etoposide IV 2 hour day 1-5 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 6 continue blood count recover . Patients also receive methotrexate IV 24 hour day 22 follow leucovorin calcium IV every 6 hour day 24 25 . Ph-positive patient receive imatinib mesylate PO day 1-14 . Treatment Block 3a ( Ph-negative patient ) : Patients receive cytarabine IV 3 hour every 12 hour day 1 , 2 , 8 , 9 , asparaginase IM day 2 9 , G-CSF SC begin day 10 continue blood count recover . Treatment Block 3b ( Ph-positive patient ) : Patients receive cytarabine IV 3 hour every 12 hour day 1 2 , asparaginase IM day 2 , G-CSF SC begin day 3 continue blood count recover . Patients also receive imatinib mesylate PO day 1-14 . ARM II : Treatment Block 1 : Patients receive cytarabine IT day 1 methotrexate , cytarabine hydrocortisone IT ( triple intrathecal therapy ; TIT ) day 8 , 15 , 22 , 29 . Vincristine , prednisone , pegaspargase , doxorubicin , imatinib mesylate administer arm I . Treatment Block 3 : Patients receive cytarabine , asparaginase , G-CSF , imatinib mesylate arm I . Treatment Block 2 : Patients receive TIT day 1 22 . Patients receive cyclophosphamide , etoposide , G-CSF , methotrexate IV , leucovorin calcium , imatinib mesylate arm I . After block complete , disease assess . The next block start day 36 blood count recover marrow block 1 least M2/M3 . Patients remove protocol therapy disease progress , unacceptable toxicity occur , marrow M2/M3 day 15 second administer block treatment , cerebrospinal fluid blast persist 6 weekly dos TIT . After completion study treatment , patient follow 4 month . PROJECTED ACCRUAL : A total 63-126 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients acute lymphoblastic leukemia ( ALL ) first relapse involve bone marrow ( M3 marrow ) , without associate extramedullary disease ; include patient Philadelphia chromosomepositive Shortening fraction &gt; = 28 % echocardiogram , ejection fraction &gt; = 50 % gate radionuclide study Cumulative prior anthracycline exposure = &lt; 350 mg/m^2 ( 10 mg/m^2 dose idarubicin calculate isotoxic equivalent 50 mg/m^2 daunorubicin adriamycin ) All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients Bcell ALL ( L3 morphology evidence myc translocation molecular cytogenetic technique ) eligible Patients Down syndrome exclude due administration methotrexate Block 2 Patients undergone prior stem cell transplantation ( SCT ) ineligible : They receive SCT le 12 month prior study entry They still receive immunosuppression treatment graftversushost disease ( GVHD ) They active fungal infection time study entry They invasive filamentous fungal infection time postSCT Pregnant lactating female ineligible medication use protocol could harmful unborn child infant Patients prior isolated extramedullary relapse ineligible</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>